N
RYTM icon

Nuveen’s Rhythm Pharmaceuticals RYTM Stock Holding History

Nuveen’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Buy
117,376
+1,442
+1% +$140K ﹤0.01% 1539
2025
Q4 		$12.4M Sell
115,934
-2,030
-2% -$215K ﹤0.01% 1428
2025
Q3 		$11.9M Sell
117,964
-3,891
-3% -$361K ﹤0.01% 1455
2025
Q2 		$7.7M Sell
121,855
-25,446
-17% -$1.56M ﹤0.01% 1662
2025
Q1 		$7.8M Buy
147,301
+398
+0.3% +$22.1K ﹤0.01% 1694
2024
Q4 		$8.22M Sell
146,903
-972
-0.7% -$53.7K ﹤0.01% 1694
2024
Q3 		$7.75M Sell
147,875
-1,244
-0.8% -$59.6K ﹤0.01% 1760
2024
Q2 		$6.12M Buy
149,119
+6,384
+4% +$255K ﹤0.01% 1844
2024
Q1 		$6.18M Sell
142,735
-934
-0.7% -$40.9K ﹤0.01% 1864
2023
Q4 		$6.6M Buy
143,669
+2,084
+1% +$65.7K ﹤0.01% 1817
2023
Q3 		$3.25M Sell
141,585
-56,858
-29% -$1.27M ﹤0.01% 2076
2023
Q2 		$3.27M Buy
198,443
+149,039
+302% +$2.69M ﹤0.01% 2120
2023
Q1 		$881K Buy
49,404
+1,913
+4% +$48K ﹤0.01% 2651
2022
Q4 		$1.38M Buy
47,491
+7,201
+18% +$185K ﹤0.01% 2541
2022
Q3 		$987K Sell
40,290
-915
-2% -$17K ﹤0.01% 2759
2022
Q2 		$171K Sell
41,205
-158,745
-79% -$869K ﹤0.01% 3162
2022
Q1 		$2.25M Sell
199,950
-2,428
-1% -$21.3K ﹤0.01% 2448
2021
Q4 		$2.02M Sell
202,378
-11,604
-5% -$130K ﹤0.01% 2560
2021
Q3 		$2.79M Sell
213,982
-36,274
-14% -$554K ﹤0.01% 2520
2021
Q2 		$4.9M Buy
250,256
+96,987
+63% +$2.01M ﹤0.01% 2259
2021
Q1 		$3.26M Buy
153,269
+18,163
+13% +$527K ﹤0.01% 2378
2020
Q4 		$4.02M Buy
135,106
+15,447
+13% +$393K ﹤0.01% 2182
2020
Q3 		$2.59M Buy
119,659
+1,882
+2% +$43.1K ﹤0.01% 2255
2020
Q2 		$2.63M Buy
117,777
+11,181
+10% +$218K ﹤0.01% 2224
2020
Q1 		$1.62M Buy
106,596
+6,855
+7% +$123K ﹤0.01% 2287
2019
Q4 		$2.29M Buy
99,741
+26,025
+35% +$578K ﹤0.01% 2373
2019
Q3 		$1.59M Sell
73,716
-3,469
-4% -$74.4K ﹤0.01% 2505
2019
Q2 		$1.7M Buy
+77,185
New +$1.95M ﹤0.01% 2510

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Nuveen's RYTM Position: Q1 2026 in Review

Nuveen increased its Rhythm Pharmaceuticals (RYTM) stake by 1.2% in Q1 2026, buying an estimated $140K and bringing the position to 117,376 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Nuveen first reported a position in RYTM in Q2 2019 and has held it in 28 quarters since. The position peaked at $12.4M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Nuveen held 117,376 shares of Rhythm Pharmaceuticals worth $10.2M as of Q1 2026.
  • Nuveen bought 1,442 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $140K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1539 holding.
  • Nuveen first reported a position in Rhythm Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Rhythm Pharmaceuticals position peaked at $12.4M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.